Journal article

Low-dose IL-2 therapy invigorates CD8( ) T cells for viral control in systemic lupus erythematosus with a potential risk of deteriorating immunopathology

Pengcheng Zhou, Jiali Chen, Jing He, Ting Zheng, Joseph Yunis, Victor Makota, Yannick O Alexandre, Fang Gong, Xia Zhang, Wuxiang Xie, Yuhui Li, Miao Shao, Yanshan Zhu, Jane E Sinclair, Miao Miao, Yaping Chen, Kirsty R Short, Scott N Mueller, Xiaolin Sun, Di Yu Show all

PLOS PATHOGENS | PUBLIC LIBRARY SCIENCE | Published : 2021

Abstract

Autoimmune diseases are often treated by glucocorticoids and immunosuppressive drugs that could increase the risk for infection, which in turn deteriorate disease and cause mortality. Low-dose IL-2 (Ld-IL2) therapy emerges as a new treatment for a wide range of autoimmune diseases. To examine its influence on infection, we retrospectively studied 665 patients with systemic lupus erythematosus (SLE) including about one third receiving Ld-IL2 therapy, where Ld-IL2 therapy was found beneficial in reducing the incidence of infections. In line with this clinical observation, IL-2 treatment accelerated viral clearance in mice infected with influenza A virus or lymphocytic choriomeningitis virus (L..

View full abstract

Grants

Awarded by National Key Research and Development Program of China


Awarded by National Natural Science Foundation of China (NSFC)


Awarded by Australian National Health and Medical Research Council (NHMRC)


Awarded by Beijing sciTech Program


Awarded by Clinical Medicine Plus X-Young scholars Project of Peking University


Funding Acknowledgements

This study was supported by the National Key Research and Development Program of China (2017YFC0909003 to D.Y.); National Natural Science Foundation of China (NSFC) grants 31530020, 91742115 (to Z.L.), 81429003 (to D. Y.), 82071813 (to J.H.), 81970759 (to T.Z.) and 81971520 (to X. S.), Peking-Tsinghua Center for Life Sciences (to Z.L.). Australian National Health and Medical Research Council (NHMRC) project GNT1085509, and the Bellberry-Viertel Senior Medical Research fellowship (to D.Y.). Beijing sciTech Program (Z191100006619114 to J.H.) and Clinical Medicine Plus X-Young scholars Project of Peking University (PKU2020LCXQ018 to J.H.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.